N1 Research LLC Trials - LARVOL Sigma

N1 Research LLC	Welcome, Profile Billing Logout

40 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Rodriguez, Ramon

IPX203-401-23, NCT06765668: A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Recruiting

220

CREXONT ER, IPX203

Impax Laboratories, LLC, Amneal Pharmaceuticals, LLC

Parkinson Disease

11/25

08/26

TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed

507

Europe, Canada, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

AbbVie

Parkinson Disease

01/24

02/24

TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed

304

Europe, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

AbbVie

Parkinson Disease

10/24

NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

2996

Japan, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer Disease

11/27

NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed

CVN424 150 mg, Placebo

Cerevance Beta, Inc.

Parkinson's Disease

01/25

02/25

NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting

150

NEU-411, Placebo

Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.

Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic

09/26

09/27

NCT02066779: iPad Based Support System to Improve Outcomes From DBS Therapy

Not yet recruiting

N/A

iPad-based Clinical Support Care, iPad-based Tool, Standard Clinical Care

University of Florida, University of Utah

Parkinson's Disease, Parkinsons Disease

12/18

NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting

N/A

Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals

Parkinson Disease

02/26

NCT05479552: A Diagnostic Test for Dementia With Lewy Bodies

Active, not recruiting

N/A

Syn-One Test

CND Life Sciences, National Institute on Aging (NIA)

MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies

09/25

10/25

TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed

N/A

220

University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health

Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia

04/24

Isaacson, Stuart

IPX203-401-23, NCT06765668: A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Recruiting

220

CREXONT ER, IPX203

Impax Laboratories, LLC, Amneal Pharmaceuticals, LLC

Parkinson Disease

11/25

08/26

LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated

Europe, US

BIIB122, DNL151, BIIB122-Matching Placebo

Biogen, Denali Therapeutics Inc.

Parkinson Disease

07/23

NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed

523

Europe, US

buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo

Annovis Bio Inc., TFS Trial Form Support

Parkinson's Disease, Idiopathic

12/23

TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed

507

Europe, Canada, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

AbbVie

Parkinson Disease

01/24

02/24

TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed

522

Europe, Canada, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

Cerevel Therapeutics, LLC

Parkinson Disease

06/24

REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated

1125

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

12/24

ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting

2/3

110

Europe, US

AMX0035, Placebo

Amylyx Pharmaceuticals Inc.

Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism

04/26

11/29

NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Terminated

513

Europe, US, RoW

K0706, placebo

Sun Pharma Advanced Research Company Limited

Early Parkinson Disease

04/24

06/24

SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed

130

CT1812

Cognition Therapeutics, National Institute on Aging (NIA)

Dementia with Lewy Bodies

11/24

NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed

CVN424 150 mg, Placebo

Cerevance Beta, Inc.

Parkinson's Disease

01/25

02/25

LRRK2-PD, NCT06602193: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease

Recruiting

Europe, US

BIIB122 225 mg, DNL151, BIIB122-Matching Placebo

Denali Therapeutics Inc., Biogen

Parkinson Disease

04/26

02/28

NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting

150

NEU-411, Placebo

Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.

Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic

09/26

09/27

LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

BIIB122, DNL151, BIIB122-Matching Placebo

Biogen, Denali Therapeutics Inc.

Parkinson Disease

12/25

NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting

Japan, US

ONO-2808, Placebo

Ono Pharmaceutical Co. Ltd

Multiple System Atrophy (MSA)

08/25

ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting

237

Europe, Canada, US

BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo

Bial R&D Investments, S.A.

Parkinson's Disease

03/26

07/26

NCT04680065: GDNF Gene Therapy for Multiple System Atrophy

Recruiting

AAV2-GDNF gene therapy, Sham (Placebo) Surgery

Brain Neurotherapy Bio, Inc.

Multiple System Atrophy

12/25

12/28

NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting

N/A

Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals

Parkinson Disease

02/26

TRANQUIL, NCT06235190: Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor

Active, not recruiting

N/A

126

US, RoW

Felix NeuroAI Wristband, Sham Device

Fasikl Inc.

Essential Tremor

10/24

11/25

NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting

N/A

25000

Canada, US, RoW

Lab Assay for seven genetic variants for Parkinson's Disease

Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group

Parkinson's Disease

06/26

07/26

NCT05699460: Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Active, not recruiting

N/A

150

Europe, US

This is an observational study.

Asklepios Biopharmaceutical, Inc.

Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy

08/25

10/25

ROPAD, NCT03866603: Rostock International Parkinson's Disease Study

Active, not recruiting

N/A

25000

Europe, Canada, US, RoW

CENTOGENE GmbH Rostock

Parkinson´s Disease

12/25

PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort

Recruiting

N/A

4500

Europe, Canada, US, RoW

Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders

Parkinson Disease

12/33

Acosta, Carem

NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting

150

NEU-411, Placebo

Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.

Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic

09/26

09/27

MTR-601-201, NCT06830642: Study of the Oral Treatment MTR-601 in Cervical Dystonia

Recruiting

MTR-601, Placebo

Motric Bio

Cervical Dystonia

07/26

08/26

NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting

N/A

Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals

Parkinson Disease

02/26

Arias, Karla

REGENERATE-PD, NCT06285643: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease

Recruiting

Europe, US

AAV2-GDNF Gene therapy, Biological, Control Surgery

AskBio Inc, Bayer

Parkinson Disease

11/27

NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting

150

NEU-411, Placebo

Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.

Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic

09/26

09/27

NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting

N/A

Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals

Parkinson Disease

02/26

NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting

N/A

25000

Canada, US, RoW

Lab Assay for seven genetic variants for Parkinson's Disease

Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group

Parkinson's Disease

06/26

07/26

Santoni, Erica

NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting

N/A

Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals

Parkinson Disease

02/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Rodriguez, Ramon

IPX203-401-23, NCT06765668: A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Recruiting

220

CREXONT ER, IPX203

Impax Laboratories, LLC, Amneal Pharmaceuticals, LLC

Parkinson Disease

11/25

08/26

TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed

507

Europe, Canada, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

AbbVie

Parkinson Disease

01/24

02/24

TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed

304

Europe, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

AbbVie

Parkinson Disease

10/24

NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

2996

Japan, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer Disease

11/27

NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed

CVN424 150 mg, Placebo

Cerevance Beta, Inc.

Parkinson's Disease

01/25

02/25

NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting

150

NEU-411, Placebo

Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.

Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic

09/26

09/27

NCT02066779: iPad Based Support System to Improve Outcomes From DBS Therapy

Not yet recruiting

N/A

iPad-based Clinical Support Care, iPad-based Tool, Standard Clinical Care

University of Florida, University of Utah

Parkinson's Disease, Parkinsons Disease

12/18

NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting

N/A

Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals

Parkinson Disease

02/26

NCT05479552: A Diagnostic Test for Dementia With Lewy Bodies

Active, not recruiting

N/A

Syn-One Test

CND Life Sciences, National Institute on Aging (NIA)

MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies

09/25

10/25

TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed

N/A

220

Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia

04/24

Isaacson, Stuart

IPX203-401-23, NCT06765668: A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Recruiting

220

CREXONT ER, IPX203

Impax Laboratories, LLC, Amneal Pharmaceuticals, LLC

Parkinson Disease

11/25

08/26

Terminated

Europe, US

BIIB122, DNL151, BIIB122-Matching Placebo

Biogen, Denali Therapeutics Inc.

Parkinson Disease

07/23

NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed

523

Europe, US

buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo

Annovis Bio Inc., TFS Trial Form Support

Parkinson's Disease, Idiopathic

12/23

TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed

507

Europe, Canada, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

AbbVie

Parkinson Disease

01/24

02/24

TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed

522

Europe, Canada, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

Cerevel Therapeutics, LLC

Parkinson Disease

06/24

REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated

1125

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

12/24

ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting

2/3

110

Europe, US

AMX0035, Placebo

Amylyx Pharmaceuticals Inc.

Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism

04/26

11/29

NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Terminated

513

Europe, US, RoW

K0706, placebo

Sun Pharma Advanced Research Company Limited

Early Parkinson Disease

04/24

06/24

SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed

130

CT1812

Cognition Therapeutics, National Institute on Aging (NIA)

Dementia with Lewy Bodies

11/24

NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed

CVN424 150 mg, Placebo

Cerevance Beta, Inc.

Parkinson's Disease

01/25

02/25

LRRK2-PD, NCT06602193: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease

Recruiting

Europe, US

BIIB122 225 mg, DNL151, BIIB122-Matching Placebo

Denali Therapeutics Inc., Biogen

Parkinson Disease

04/26

02/28

NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting

150

NEU-411, Placebo

Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.

Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic

09/26

09/27

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

BIIB122, DNL151, BIIB122-Matching Placebo

Biogen, Denali Therapeutics Inc.

Parkinson Disease

12/25

NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting

Japan, US

ONO-2808, Placebo

Ono Pharmaceutical Co. Ltd

Multiple System Atrophy (MSA)

08/25

ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting

237

Europe, Canada, US

BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo

Bial R&D Investments, S.A.

Parkinson's Disease

03/26

07/26

NCT04680065: GDNF Gene Therapy for Multiple System Atrophy

Recruiting

AAV2-GDNF gene therapy, Sham (Placebo) Surgery

Brain Neurotherapy Bio, Inc.

Multiple System Atrophy

12/25

12/28

NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting

N/A

Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals

Parkinson Disease

02/26

TRANQUIL, NCT06235190: Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor

Active, not recruiting

N/A

126

US, RoW

Felix NeuroAI Wristband, Sham Device

Fasikl Inc.

Essential Tremor

10/24

11/25

NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting

N/A

25000

Canada, US, RoW

Lab Assay for seven genetic variants for Parkinson's Disease

Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group

Parkinson's Disease

06/26

07/26

NCT05699460: Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Active, not recruiting

N/A

150

Europe, US

This is an observational study.

Asklepios Biopharmaceutical, Inc.

Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy

08/25

10/25

ROPAD, NCT03866603: Rostock International Parkinson's Disease Study

Active, not recruiting

N/A

25000

Europe, Canada, US, RoW

CENTOGENE GmbH Rostock

Parkinson´s Disease

12/25

PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort

Recruiting

N/A

4500

Europe, Canada, US, RoW

Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders

Parkinson Disease

12/33

Acosta, Carem

NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting

150

NEU-411, Placebo

Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.

Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic

09/26

09/27

MTR-601-201, NCT06830642: Study of the Oral Treatment MTR-601 in Cervical Dystonia

Recruiting

MTR-601, Placebo

Motric Bio

Cervical Dystonia

07/26

08/26

NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting

N/A

Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals

Parkinson Disease

02/26

Arias, Karla

REGENERATE-PD, NCT06285643: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease

Recruiting

Europe, US

AAV2-GDNF Gene therapy, Biological, Control Surgery

AskBio Inc, Bayer

Parkinson Disease

11/27

NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting

150

NEU-411, Placebo

Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.

Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic

09/26

09/27

NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting

N/A

Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals

Parkinson Disease

02/26

NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting

N/A

25000

Canada, US, RoW

Lab Assay for seven genetic variants for Parkinson's Disease

Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group

Parkinson's Disease

06/26

07/26

Santoni, Erica

NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting

N/A

Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals

Parkinson Disease

02/26

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites